

CURRICULUM VITAE

Luke Moore

FRCPath FRCP PhD MSc MPH DTM&H DipULT FHEA MBChB

PERSONAL DETAILS

I am an Infectious Diseases Physician and Clinical Microbiologist with special interests in critical care infections and antimicrobial resistance, caring for secondary and tertiary care patients in London. I hold a PhD in this field, two Masters degrees, and am a Fellow of both the Royal College of Pathologists and the Royal College of Physicians. My current research focuses on the epidemiology of and interventions for outbreak control and antimicrobial stewardship. I provide undergraduate and post graduate education across a range of degree courses, am West London Specialty Training Committee lead for infection, examine for the Royal College of Pathologists, am a Trustee for the Healthcare Infection Society, and an associate editor for two infection journals.

ACADEMIC QUALIFICATIONS

2020	Diploma of University Lecturing & Teaching	Imperial College London
2016	PhD Clinical Microbiology	Imperial College London
2012	MSc Public Health (<i>Distinction</i>)	London School of Hygiene & Tropical Medicine
2010	MSc Clinical Microbiology (<i>Distinction</i>)	Queen Mary, University of London
2007	Diploma of Tropical Medicine & Hygiene	London School of Hygiene & Tropical Medicine
2003	MBChB Bachelor of Medicine & Bachelor of Surgery	University of Leeds

PROFESSIONAL QUALIFICATIONS

2021	Fellowship of the Royal College of Physicians	Royal College of Physicians
2017	Fellowship of the Higher Education Academy	Higher Education Academy
2017	Certificate of Completion of Training: Infectious Diseases, Microbiology & Virology	General Medical Council
2014	Specialty Certificate in Infectious Diseases	Royal College of Physicians
2011	Fellowship of the Royal College of Pathologists	Royal College of Pathologists
2007	Membership of the Royal College of Physicians	Royal College of Physicians

RESEARCH GRANTS & TRIALS

2022-date	Principal Investigator: Molecular diagnosis of dermatophytosis. <i>NW London Pathology</i> . (£30,705)
2022-date	Principal Investigator: Evaluating rapid diagnostics in bacteraemia (EIDETIC). <i>NW London Pathology</i> . (£9,967)
2021-date	Chief Investigator (UK): Retrospective Cefiderocol Chart Review Study (PROVE). <i>Shionogi</i> . (2 recruited)
2021-date	Chief Investigator: COVID-19 severity and genetic predisposition (COV-GEN). <i>dnaNudge</i> . (£101,000).
2021-date	Principal Investigator (site): Prospective clinical registry of iv fosfomycin (FORTRESS). <i>Infectopharm</i> . (2 recruited)
2021-date	Co-Investigator: Preterm rupture of membranes therapy (PROMPT). <i>Chelsea & Westminster NHS Trust</i> .
2021-date	Chief Investigator: SARS-CoV-2 in older people (SCALPEL). <i>Chelsea & Westminster NHS Trust</i> . (270 recruited)
2021-date	Principal Investigator (site): Genetics of mortality in critical care (GenOMICC). <i>Uni. Edinburgh</i> . (50 recruited)
2020-date	Principal Investigator: COVID-19 diagnostics evaluation and impact analysis. <i>CW Plus Charity</i> . (£50,000).
2020-date	Principal Investigator: Chelsea infectious diseases research (CINDER). <i>CW Plus Charity</i> . (£105,000).
2020-date	Co-Investigator: Favipiravir RCT in COVID-19. (PIONEER). <i>LifeArc</i> . (£1,370,000; 502 recruited).
2020-date	Principal Investigator (site): Clinical Characterisation of Severe Emerging Infection (ISARIC). <i>WHO</i> . (568 recruited).
2020-2021	Principal Investigator: Panton-Valentine Leukocidin S. aureus community transmission. <i>CW Plus Charity</i> . (£2,000).
2020-2021	Principal Investigator (site): COVID19 community transmission (REACT 2). <i>Imperial College London</i> . (57 recruited).
2019-2021	Principal Investigator (site): Observational Zavicefta Phase IV study (EZTEAM). <i>Pfizer</i> . (9 patients recruited).
2019-2020	Principal Investigator: Fomite microbial transmission in burns theatres. <i>CW Plus Charity</i> . (£1,500).
2018-2020	Co-Investigator: MolecuLight investigation of burn wound infections. <i>Westminster Spouses Committee</i> . (£12,000).
2017-2021	Co-Investigator: Molecular diagnostics for ventilator-associated pneumonia (INHALE). <i>NIHR</i> . (71 recruited).
2017-2018	Co-Investigator: Point of care testing for ICU sepsis (TEST-IT). <i>Northern Ireland Clinical Trials Unit</i> . (41 recruited).
2014-2019	Co-Investigator: Integrated care for infection management at point of care (EPIC IMPOC). <i>NIHR</i> . (£687,000).
2016	Co-Investigator: Pivmecillinam susceptibility in a UK healthcare network. <i>Leo Pharma</i> . (£15,000).
2016	Co-Investigator: Setting priorities in infection research: involving citizens (SPIRIT). <i>NIHR Imperial BRC</i> . (£2,000).
2013	Research Training Fellowship: Rapid microbiology diagnostics in critical care. <i>NIHR Imperial BRC</i> . (£224,000).
2013	Co-Investigator: Antimicrobial prescribing via smartphones (POCAST). <i>Imperial Healthcare Charity</i> . (£56,000).
2012	Co-Investigator: Antimicrobial prescribing via machine learning (ENIAPP). <i>Imperial College London</i> . (£20,000).

AWARDS

2017	Chairman's Award Finalist: <i>Imperial College Healthcare NHS Trust</i> .
2016	Outstanding Contribution to Teaching & Supervision Nominee: <i>Imperial College London</i> .
2016	ECCMID Young Scientist Award: <i>European Society for Clinical Microbiology and Infectious Diseases</i> .
2016	Wellcome Trust/DBT India Alliance Award: <i>International Congress on Infectious Diseases, Hyderabad</i> .
2015	Rising Educator of the Year Award: <i>Imperial College Healthcare NHS Trust, London</i> .
2015	Young Scientist Award: <i>Faculty of Medicine, Imperial College London</i> .

CLINICAL APPOINTMENTS

Jul 2017 - date	Consultant Infectious Diseases and Clinical Microbiology & Virology. <i>Chelsea & Westminster NHS Foundation Trust.</i> <i>North West London Pathology at Imperial College Healthcare NHS Trust.</i> Leading on and delivering clinical infection management in critical care, acute medicine, outpatient parenteral antimicrobial therapy, and in the regional London burns unit. Leading on molecular diagnostics development at North West London Pathology. Lead strategic and operational interventions to improve antimicrobial stewardship, meeting Commissioning for Quality and Innovation framework objectives. Coordination and delivery of strategic and operational interventions to meet regional ambulatory care objectives for sustainable transformation in North West London. Designated Medical Practitioner, supporting pharmacists to attain the Practice Certificate in Independent Prescribing. From Feb 2019 to Jan 2020 additional responsibilities at Central London Community Healthcare Trust to lead, deliver, and evaluate an antimicrobial stewardship programme for services across areas of South East England. From Feb 2020 lead on Trust development & implementation of pathways for COVID-19 testing and anti-infectives. From Sept 2021 Divisional Lead for Research (Clinical Support Services).
Nov 2016	Consultant (Locum) Infectious Diseases and Clinical Microbiology & Virology.
- Jul 2017	<i>Chelsea & Westminster NHS Foundation Trust.</i> <i>North West London Pathology at Imperial College Healthcare NHS Trust.</i>
Aug 2008 - Nov 2016	Specialty Registrar Infectious Diseases and Medical Microbiology & Virology. <i>North West London rotation, Health Education England (NTN: LDN/075/016/C)</i> Clinical Microbiology & Clinical Virology (Chelsea & Westminster Hospital; 2 years. West Middlesex Hospital; 1 year), Clinical Microbiology & HIV Medicine (St Mary's Hospital; 1 year), Infectious Diseases (Charing Cross Hospital; 1 year. Hammersmith Hospital; 1 year), Out of Programme (Imperial College London; 3 years).
Aug 2007 - Aug 2008	Specialty Registrar Medicine (Tropical Medicine, Intensive Care Medicine, Haematology). <i>University College London Hospitals NHS Trust, London.</i>
Oct 2004 - Dec 2006	Senior House Officer Medicine (Acute, Cardiology, Gastroenterology, Respiratory, Gerontology, Haematology). <i>Whipps Cross University Hospital NHS Trust, London.</i>
Feb 2004 - Aug 2004	Pre-Registration House Officer Medicine (Respiratory Medicine, Gerontology). <i>Mid Yorkshire Hospitals NHS Trust, Yorkshire.</i>
Aug 2003 - Feb 2004	Pre-Registration House Officer Surgery (General Surgery, Urology). <i>St James' University Hospital, Leeds.</i>

ACADEMIC APPOINTMENTS

Aug 2019 - date	Honorary Clinical Senior Lecturer. <i>National Institute for Health Research Health Protection Research Unit, Imperial College London.</i> Exploring optimisation of antimicrobials in primary and secondary care clinical pathways, focusing on machine learning algorithms and novel rapid diagnostics. Exploring methods to track and terminate infectious diseases outbreaks using machine learning and applied use of molecular techniques. Exploring host-drug interactions for antimicrobials using real time diagnostics and genome wide association studies.
Apr 2016 - Aug 2019	Honorary Clinical Research Fellow. <i>National Institute for Health Research Biomedical Research Centre, Imperial College London.</i>
Apr 2013 - Apr 2016	Clinical Research Training Fellow. <i>National Institute for Health Research Biomedical Research Centre, Imperial College London.</i>
Sept 2014 - Sept 2015	Education Fellow. <i>Imperial College Healthcare NHS Trust, London.</i>
Apr 2012 - Apr 2013	Honorary Clinical Lecturer. <i>Centre for Infection Prevention & Management, Imperial College London.</i>

NATIONAL & INTERNATIONAL APPOINTMENTS

2020-date	Associate Editor: Journal of Infection.
2020-date	Associate Editor: Annals of Clinical Microbiology and Antimicrobials.
2020-date	Board Member: Middle East & North Africa Center for Research & Development and Internship. <i>Jordan.</i>
2020-date	Examiner: Royal College of Pathologists. <i>UK.</i>
2020-date	Trustee & Media Spokesperson: Healthcare Infection Society. <i>UK.</i>
2015-date	Committee Member: Specialty Training Committee; Infectious Diseases & Microbiology. <i>London.</i>
2013-date	Scientific Advisory Boards: Various governments, pharmaceutical and diagnostic companies. Details on request.
2020-2021	Committee Member: Asia-Pacific Consensus in Rapid Infection Diagnostics.
2018-2020	Committee Member: UK Consensus in Burns Infections. <i>UK.</i>
2014-2016 2004	Committee Member: Securing effective antimicrobials working group. <i>Chatham House, UK.</i> General Medical Council Pre-Registration House Officer Representative: Yorkshire Deanery, <i>UK.</i>

JOURNAL ARTICLES

- In Press Goodfellow J, Hughes S, Smith J, Jones R, **Moore LSP**, Rayment M. Novel use of oral chloramphenicol for treatment-resistant *Mycoplasma genitalium*. *Sexually Transmit Infect.* 2022;[InPress].
- In Press Hussain K, Bandyopadhyay, Roberts N, Mughal N, **Moore LSP**, Fuller LC. Panton-Valentine Leukocidin producing *Staphylococcus aureus*: a clinical review. *Clin Exp Derm.* 2022;[InPress]. PMID:36040400.
- In Press Singh S, **Moore LSP**, Mughal N, Ho M, Armstrong-James D, Singh S. Novel inhaled antifungal for pseudomembranous *Aspergillus tracheobronchitis* complicating connective tissue disease. *Thorax.* 2022;[InPress]. PMID:36180064.
- In Press Low R, Young K, Verani L, Cotton DT, Welman T, **Moore LSP**, Horwitz MD. Point of care testing for tetanus Immunity: a systematic review. *Emerg Med J.* 2022;[InPress]. PMID:35379750.
- 2022 Singh S, Ark R, Tatlock J, Mandalia S, Chung C, Azadian BS, Hughes S, Mughal N, **Moore LSP**, Singh S. Evaluating the long-term impact of an antimicrobial stewardship programme in a Central London mixed medical and surgical intensive care unit. *J Antimicrob Chemother – Antimicrob Resist.* 2022;4(5):dlac108. PMID:36226228.
- 2022 Pallett SJC, Rayment M, Heskin J, Mazzelli A, Jones R, Mughal N, Randell P, Davies GW, **Moore LSP**. Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay. *Diagn Microbiol Infect Dis.* 2022;104(3):115788. PMID:36084423.
- 2022 Hughes S, Heard KL, Mughal N, **Moore LSP**. Optimization of antimicrobial dosing in patients with acute kidney injury: a single-centre observational study. *J Antimicrob Chemother – Antimicrob Resist.* 2022;4(4):dlac080. PMID:35898430
- * 2022 Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, Gedela K, Patel S, Gohil J, Nugent D, Suchak T, Dickinson M, Feeney M, Mora-Peris B, Stegmann K, Plaha K, Davies G, **Moore LSP**, Mughal N, Asboe D, Boffito M, Jones R, Whitlock G. Demographic and clinical characteristics of confirmed human Monkeypox virus cases in individuals attending a sexual health centre in London, United Kingdom. *Lancet Infect Dis.* 2022;22(9):1321-1328. PMID:35785793.
- 2022 Heskin J, Belfield A, Milne C, Brown N, Walters Y, Scott C, Bracchi M, **Moore LSP**, Mughal N, Rampling T, Winston A, Nelson M, Duncan S, Jones R, Ashley Price D, Mora-Peris B. Transmission of monkeypox virus through sexual contact - A novel route of infection. *J Infect.* 2022;85(3):334-363. PMID:35659548.
- 2022 Rawson TM, Brzeska-Trafny I, Maxfield R, Almeida M, Gilchrist M, Gonzalo X, **Moore LSP**, Donaldson H, Davies F. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Dehli Metallo-beta-lactamase (NDM) infection. *J Glob Antimicrob Resist.* 2022;29:558-562. PMID:35131508.
- 2022 McKean AR, Williams GJ, Macneal P, **Moore LSP**, Idowu A, Milroy C. Paediatric paronychia: a single centre retrospective, microbiological analysis and national survey. *J Plast Reconstr Aesthet Surg.* 2022;75(7):2387-2440. PMID:35589547.
- 2022 Heskin J, Pallett SJC, Al-Hindawi A, Davies GW, Rayment M, Mughal N, Randell P, Jones R, **Moore LSP**. Evaluating the performance characteristics of five lateral flow assays for the detection of the SARS- CoV-2 nucleocapsid antigen. *Nat Sci Rep.* 2022;12:8811.
- 2022 Apisarthanarak A, Kim HB, **Moore LSP**, Xiao Y, Singh S, Doi Y, Kwa ALH, Ponnampalavanar SSL, Cao Q, Kim SW, Lee H, Santanirand P. Utility and applicability of rapid diagnostic testing in antimicrobial stewardship in Asia Pacific: A Delphi consensus. *Clin Infect Dis.* 2022;74(11):2067–76. PMID:34665855.
- 2022 Wong SMY, Handford C, Vermaak M, **Moore LSP**, Pallett SJC. Addressing high-risk anti-poaching roles in Central Africa: lessons from delivery of remote advanced first-aid teaching for trauma care and snakebite first-aid. *Trans R Soc Trop Med Hyg.* 2022;116(5):381-385. PMID:34791458.
- 2022 Heskin J, Pallett SJC, Mughal N, Davies GW, **Moore LSP**, Rayment M, Jones R. Caution required with use of ritonovir-boosted PF-07321332 in COVID-19 management. *Lancet.* 2022;399(10319):21-22. PMID:3497371.
- 2022 Pallett SJC, Heskin J, Mazzella A, Groppelli E, **Moore LSP**. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants. *Lancet Microbe.* 2022;3(3):e167. PMID:34977829.
- 2022 Heskin J, Pallett SJC, Mughal N, Jones R, Rayment M, Davies GW, **Moore LSP**. Healthcare worker perceptions of routine asymptomatic SARS-CoV-2 screening using lateral flow assays: a qualitative analysis across two London hospitals. *J Infection.* 2022;84(1):e26-e28. PMID:34736983.
- * 2022 Pallett SJC, Jones R, Abdulaal A, Pallett MA, Rayment M, Patel A, Mughal N, Khan M, Rosadas de Oliveira C, Pantelidis P, Randell P, Toumazou C, O'Shea MK, Tedder R, McClure MO, Davies GW, **Moore LSP**. Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, UK, 17 April to 17 July 2020. *Eurosurveillance.* 2022;27(4):pii=2002076. PMID:35086612.
- 2022 Pallett SJC, Handford CG, Wong SMY, West C, **Moore LSP**. Necrosis and amputation following the bite of the Bibron's stiletto snake (*Atractaspis bibronii*). *Tropical Doctor.* 2022;52(1):142-146. PMID:34490812.
- 2022 Hughes S, Heard KL, Mughal N, **Moore LSP**. Burden of enteral supplement interactions with common antimicrobial agents; a single centre observational analysis. *Eur J Hosp Pharm.* 2021;29(5):280-283. PMID:33414257.
- 2021 Al-Hindawi A, Abdulaal A, Rawson TMR, Alqahtani SA, Mughal N, **Moore LSP**. COVID-19 prognostic models: a pro-con debate for machine learning vs traditional statistics. *Frontiers Digital Health.* 2021;3:637944.
- 2021 Rawson TM, Wilson RC, **Moore LSP**, MacGowan AP, Lovering AM, Bayliss M, Kyriakides M, Gilchrist M, Roberts JA, Hope WW, Holmes AH. Exploring the pharmacokinetics of phenoxymethylpenicillin (Penicillin-V) in adults: a healthy volunteer study. *Open Forum Infect Dis.* 2021;8(12):ofab573. PMID:34934774.

- 2021 Soriano A, Carmeli Y, Omrani AS, **Moore LSP**, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review. *Infect Dis Ther.* 2021;10(4):1989-2034. PMID:34379310.
- 2021 Lamb G, Heskin J, Randell P, Mughal N, **Moore LSP**, Jones R, Davies GW, Rayment M. Real-world evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a prospective cohort study. *J Infection.* 2021;83(4):452-457. PMID: 34364950.
- 2021 Hernandez B, Herrero-Viñas P, Rawson TM, **Moore LSP**, Holmes AH, Georgiou P. Resistance trend estimation using regression analysis to enhance antimicrobial surveillance: a multi-centre study in London 2009-2016. *Antibiotics.* 2021;10(10):1267. PMID:34680846.
- 2021 Ranganathan N, **Moore LSP**, Hughes S. Listeria monocytogenes infections: presentation, diagnosis, and treatment. *Brit J Hosp Med.* 2021;82(10):1-6. PMID:34726931.
- 2021 Hughes S, Mughal N, **Moore LSP**. Procalcitonin to guide antibacterial prescribing in patients hospitalised with COVID-19. *Antibiotics.* 2021;10(9):1119.
- 2021 Hurt W, Savarimuthu S, Mughal N, **Moore LSP**. A rare case of Wiesella confusa endocarditis. *Clin Infect Pract.* 2021;12: 100078.
- 2021 Apisarnthanarak A, Qing C, Doi Y, Kim HB, Kim SW, Kwa A, Lee H, **Moore LSP**, Santanirand P, Singh S, Ponnampalavanar SSL, Xiao Y. Rapid diagnostic testing for antimicrobial stewardship: Analysis of utility in the Asia Pacific region. *Infect Contr Hosp Epidemiol.* 2021;42(7):864-868. PMID:34128462.
- 2021 Burdett A, Toumazou C, Sahoo R, Muhan R, Hon TK, Bedzo-Nutakor J, Casali N, Karvela M, Sohbati M, Cooke GS, Davies GW, **Moore LSP**. Pooled sputum to optimise the efficiency and utility of rapid, laboratory-free, point-of-care molecular SARS-CoV-2 testing. *BMC Inf Dis.* 2021;21(1):665. PMID:34238234.
- 2021 Denny SJ, Rawson TM, Satta G, Pallett SJC, Abdulaal A, Hughes S, Gilchrist M, Mughal N, Moore LSP. Bacteraemia variation during the COVID-19 pandemic; a multi-centre UK secondary care ecological analysis. *BMC Inf Dis.* 2021;21(1):556. PMID:34116643.
- 2021 Murongazvombo AS, Jones R, Rayment M, Mughal N, Azadian B, Donaldson H, Davies GW, **Moore LSP**, Aiken AM. Association between SARS-CoV-2 exposure and antibody status among healthcare workers in two London hospitals: a cross-sectional study. *Infect Prevent Pract.* 2021;3(3):100157. PMID:34316587.
- 2021 Pallett SJC, Brown C, Mughal N, Jones R, Randell P, **Moore LSP**. Optimising the initial investigation of suspected cases of SARS-CoV-2 reinfection. *Travel Med Infect Dis.* 2021;42:102078. PMID:33933686.
- 2021 Abdulaal A, Patel A, Al-Hindawi A, Charani E, Alqahtani SA, Davies GW, Mughal N, **Moore LSP**. Clinical utility and functionality of an artificial intelligence application to predict mortality in COVID-19: a mixed methods analysis. *J Med Internet Res Form Method.* 2021;5(7):e27992. PMID:34115603.
- 2021 Denny SJ, Abdolrasouli A, Elamin T, Gonzalo X, Pallett SJC, Charani E, Patel A, Donaldson H, Hughes S, Armstrong-James D, **Moore LSP**, Mughal N. A retrospective multicenter analysis of candidaemia among COVID-19 patients during the first UK pandemic wave. *J Infect.* 2021;82(6):276-316. PMID:33610684.
- 2021 Pallett SJC, Jones R, Randell P, Davies GW, **Moore LSP**. Structured serological testing is an essential component to investigating SARS-CoV-2 re-infection. *Lancet Inf Dis.* 2021;21(5):598-599. PMID:33484647.
- 2021 Pallett SJC, Denny SJ, Patel A, Charani E, Mughal N, Stebbing J, Davies G, **Moore LSP**. Point of care serological assays for SARS-CoV-2 in a UK hospital population: potential for enhanced case finding. *Nat Sci Rep.* 2021;11(1):5860. PMID:33712679.
- 2021 Abdolrasouli A, Gibani M, de Groot T, Borman AM, Hoffman P, Azadian BS, Mughal N, **Moore LSP**, Johnson EM, Meis JF. A pseudo-outbreak of Rhinocladiella similis in a bronchoscopy unit of a tertiary care teaching hospital in London, United Kingdom. *Mycoses.* 2021;64(4):394404. PMID:33314345.
- 2021 Rawson TM, **Moore LSP**, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Response to Dudoignon et al. (Bacterial and fungal co-infection in individuals with coronavirus). *Clin Infect Dis.* 2021;72(5):906-908. PMID:32544234.
- * 2021 Moshe M, Daunt A, Flower B, Simmons B, Brown JC, Frise R, Penn R, Kugathasan R, Petersen C, Stockmann H, Ashby D, Riley S, Atchison C, Taylor GP, Satkunarajah S, Naar L, Klaber R, Badhan A, Rosadas C, Marchesin F, Fernandez N, Sureda-Vives M, Cheeseman H, O'Hara J, Shattock R, Fontana G, Pallett SJC, Rayment M, Jones R, **Moore LSP**, Ashrafiyan H, Cherapanov P, Tedder R, McClure M, Ward H, Darzi A, Elliott P, Cooke GS, Barclay WS. SARS-CoV-2 Lateral Flow Assays for possible use in national COVID-19 seroprevalence surveys (REACT2): a diagnostic accuracy study. *Brit Med J.* 2021;372:n423. PMID:33653694.
- 2021 Rela M, Opel S, Williams S, Collins D, Martin K, Mughal N, **Moore LSP**. Operating room fomites as potential sources for microbial transmission in burns theatres. *Eur Burn J.* 2021;2(1):1-8.
- 2021 Heard KL, Killington K, Mughal N, **Moore LSP**, Hughes S. Clinical outcomes of temocillin use for invasive Enterobacteriales infections; a single centre retrospective analysis. *J Antimicrob Chemother Antimicrob Resist* 2021;3(1):dlab005. PMID:34223083.
- 2021 Asumang J, Heard KL, Troise O, Fahmy S, **Moore LSP**, Hughes S. Evaluation of a thrice weekly administration of teicoplanin in the outpatient setting: retrospective observational multi-centre study. *J Antimicrob Chemother Antimicrob Resist.* 2021;3(1):dlab012. PMID:34223089.

- 2021 McKean AR, Batten G, Macneal P, Rahman SM, **Moore LSP**, Horwitz MD. Utilising multiplex PCR technology for rapid microbial diagnosis in hand and upper limb infections. *J Plast Reconstr Aesthet Surg.* 2021;74(1):223–243. PMID:32527667.
- 2020 Rawson TM, Hernandez B, **Moore LSP**, Herrero P, Charani E, Ming D, Wilson RC, Blandy O, Sriskandan S, Gilchrist M, Toumazou C, Georgiou P, Holmes AH. A real-world evaluation of a Case-Based Reasoning algorithm to support antimicrobial prescribing decisions in acute care. *Clin Infect Dis.* 2020;26(12):1651-1657. PMID:32246143.
- 2020 Prendekci M, Clarke C, Gleeson S, Greathead L, Santos E, McLean A, Randell P, **Moore LSP**, Mughal N, Guckian M, Kelleher P, Mcadoo SP, Willicombe M. Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. *J Am Soc Nephrol.* 2020;31(12):2753-2756. PMID:33122285.
- 2020 **Moore LSP**. Near-patient SARS-CoV-2 molecular platforms: new-old tools for new-old problems. *Lancet Resp Med.* 2020;8(12):1161-1163. PMID:33038973.
- 2020 Pallett SJC, Jones R, Pallett MA, Rayment M, Mughal N, Davies GW, **Moore LSP**. Characterising differential antibody response is integral to future SARS-CoV-2 serostudies. *J Infect.* 2020;81(6):28-30. PMID:32739486.
- * 2020 Flower B, Brown J, Simmons B, Moshe M, Frise R, Penn R, Kugathasan R, Petersen C, Daunt A, Ashby D, Riley S, Atchison C, Taylor GP, Satkunarajah S, Naar L, Klaber R, Badhan A, Rosadas C, Khan M, Fernandez N, Sureda-Vives M, Cheeseman H, O'Hara J, Fontana G, Pallett SJC, Rayment M, Jones R, **Moore LSP**, Cherapanov P, Tedder R, McClure M, Ashrafiyan H, Shattock R, Ward H, Darzi A, Elliott P, Barclay WS, Cooke GS. Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 sero-prevalence survey. *Thorax.* 2020;75(12):1082-1088. PMID:32796119.
- 2020 Skolimowska K, Rayment M, Jones R, Madona P, **Moore LSP**, Randell P. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. *Clin Microbiol Infect.* 2020;26(12):1711-1713. PMID:32688069.
- * 2020 Rawson TM, **Moore LSP**, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis.* 2020;71(9):2459-2468. PMID:32358954.
- 2020 Rajput J, **Moore LSP**, Mughal N, Hughes S. Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study. *Clin Microbiol Infect.* 2020;26(12):1651-1657. PMID:32220637.
- 2020 Abdulaal A, Patel A, Charani E, Denny SJ, Alqahtani SA, Davies GW, Mughal N, **Moore LSP**. Comparison of deep learning techniques with regression analysis in creating predictive models for SARS-CoV-2 outcomes. *BMC Medical Informatics and Decision Making.* 2020;20(1):299. PMID:33213435.
- * 2020 Gibani MM, Toumazou C, Sohbat M, Sahoo R, Icely C, Karvela M, Hon TK, De Mateo S, Burdett A, Leung F, Barnett J, Orbeladze A, Luan S, Pournias S, Sun J, Flower B, Bedzo-Nutakor J, Amran M, Quinlan R, Skolimowska K, Herrera C, Rowan A, Badhan A, Klaber R, Davies G, Muir D, Randell P, Crook D, Taylor GP, Barclay W, Mughal N, **Moore LSP**, Jeffery K, Cooke GS. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. *Lancet Microbe.* 2020;1(7):300-307. PMID:32964211.
- 2020 Ponsford MJ, Gkatzionis A, Walker V, Grant AJ, Wootton RE, **Moore LSP**, Fatumo S, Mason AM, Zuber V, Willer C, Rasheed H, Brumpton B, Hveem K, Damås JK, Davies N, Åsvold BO, Solligård E, Jones S, Burgess S, Rogne T, Gill D. Cardiometabolic traits, sepsis & severe COVID-19: a Mendelian randomization investigation. *Circulation.* 2020;142(18):1791-1793. PMID:32966752.
- 2020 Patel A, Abdulaal A, Ariyanayagam D, Killington K, Pallett SJC, Denny SJ, Mughal N, Hughes S, Goel N, Davies GW, **Moore LSP**, Charani E. Investigating the association between ethnicity and health outcomes in SARS-CoV-2 in a London community and secondary care population. *PLoS One.* 2020;15(10):e0240960. PMID:33112892.
- 2020 Abdulaal A, Patel A, Charani E, Denny SJ, Mughal N, **Moore LSP**. Prognostic modelling of COVID-19 using artificial intelligence in the United Kingdom; model development and validation. *J Med Internet Res.* 2020;22(8):e20259. PMID:32735549.
- * 2020 Pallett SJC, Rayment M, Patel A, Charani E, Denny SJ, Fitzgerald-Smith SAM, Mughal N, Jones R, Davies GW, **Moore LSP**. Serological assays for delayed SARS-CoV-2 case identification: author's reply. *Lancet Resp Med.* 2020;8(10):e74. PMID:32941851.
- 2020 Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, Mai AL, Gilmour KC, Hatcher J, Scott C, Randell P, Mughal N, Jones R, **Moore LSP†**, Davies GW†. Point-of-care serological assays for delayed SARS-CoV-2 case identification among UK healthcare workers; a prospective multicentre cohort study. *Lancet Resp Med.* 2020;8(9):885-894. PMID:32717210.
- 2020 Davies A, Dheansa B, Collins D, **Moore LSP**, Falder S, Marlow K, Coy K, Teare L, Dumville J, Agha R, Jenkins T, Young A. Consensus demonstrates four indicators needed to standardise burn wound infection reporting across trials in a single country study (The ICon-B Study). *J Hosp Infect.* 2020;106(2):217-225. PMID:32763331.
- 2020 Boyd SE, Vasudevan A, **Moore LSP**, Brewer F, Gilchrist MJ, Costelloe C, Gordon AC, Holmes AH. Validating a prediction tool to determine risk of nosocomial multidrug resistant Gram-negative bacilli infection in critically ill patients: retrospective case-control study. *J Glob Antimicrob Resist.* 2020;22:826-831. PMID:32712381.
- 2020 Heard KL, Hughes S, Mughal N, **Moore LSP**. COVID-19 and fungal superinfection. *Lancet Microbe.* 2020;1(3):e107. PMID: 32835341

- 2020 Hughes S, Troise O, Donaldson H, Mughal N, **Moore LSP**. Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting. *Clin Microbiol Infect.* 2020;26(10):1395-9. PMID:32603803.
- 2020 Patel A, Charani E, Ariyanayagam D, Abdulaal A, Denny SJ, Mughal N, **Moore LSP**. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. *Clin Microbiol Infect.* 2020;26(9):1236-41. PMID:32502645.
- 2020 Rawson TM, **Moore LSP**, Castro-Sanchez E, Charani E, Davies F, Satta G, Ellington M, Holmes A. COVID-19 and the long-term impact on Antimicrobial Resistance. *J Antimicrob Chemother.* 2020;75(7):1681-1684. PMID:32433765.
- 2020 Rawson TM, Ming D, Ahmad R, **Moore LSP**, Holmes AH. Antimicrobial use, drug-resistant infections and COVID-19. *Nat Rev Microbiol.* 2020;18(8):409-410. PMID:32488173.
- 2020 Aggarwal D, Kanitkar T, Naroz M, Azadian BS, **Moore LSP**, Mughal N. Clinical utility and cost-effectiveness of 16S PCR based diagnostic testing in a UK hub-and-spoke microbiology laboratory model. *Sci Rep.* 2020;10(1):7965. PMID:32409679.
- 2020 McKean A, Assiotis A, Hassan S, Elvey M, **Moore LSP**, Eckersley M. Cutebacterium (Propionibacterium) acnes infection of the native wrist joint. *J Hand Surg.* 2020;45(6):557. PMID:31585744.
- 2020 Hughes S, Kamranpour P, Gibani MM, Mughal N, **Moore LSP**. Short-course antibiotic therapy: a bespoke approach is required. *Clin Infect Dis.* 2020;70(8):1793-1794. PMID:32274513.
- 2019 Hughes S, Chin HY, Heard KL, Kamranpour P, Bartholomew B, Mughal N, **Moore LSP**. Once daily tigecycline for outpatient parenteral antimicrobial therapy; a single centre observational study. *J Antimicrob Chemother Antimicrob Resist.* 2019;1(3):dlz085.
- 2019 Noy ML, Abdolrasouli A, Borman AM, Fraser M, Francis N, **Moore LSP**, Merika EE. Cutaneotrichosporon (Trichosporon) debeurmannianum associated with a subcutaneous mycotic cyst successfully treated with voriconazole. *Clin Experiment Derm.* 2019;45(2):250-253. PMID:31332809.
- 2019 Kamranpour P, **Moore LSP**, Hughes S. Why the newly licensed antibiotic ceftazidime should be introduced to UK formularies. *Pharmaceutical J.* 2019;303(7930):Online.
- 2019 Pallett SJC, Ebrahimsa MU, Hughes S, Mughal N, **Moore LSP**. Shorter course antimicrobial therapy for uncomplicated Gram-negative bacteraemia: is it generalizable? *Clin Infect Dis.* 2019; 69(7):1263. PMID:30726883.
- 2019 Lee AE, Niruttan K, Rawson TM, **Moore LSP**. Antibacterial resistance in ophthalmic infections: a multi-centre analysis across UK care settings. *BMC Infect Dis.* 2019;19(1):768. PMID:31481023.
- 2019 Juma F, Cave J, Gonzales H, **Moore LSP**. Non-typhoidal Salmonellosis presenting as Acute Calculus Cholecystitis. *BMJ Case Reports.* 2019;12(7):e230186. PMID:31326908.
- * 2019 Gill D, Benyamin B, **Moore LSP**, Monori G, Zhou A, Foskeridis F, Evangelou E, Laffan M, Walker AP, Tsilidis KK, Dehghan A, Elliott P, Hypponen E, Tzoulaki I. Associations of genetically determined iron status across the phenotype: A Mendelian randomization study. *PLoS Med.* 2019;16(6):e1002833. PMID:31220083.
- 2019 Davies AK, Teare L, Falder S, Coy K, Dumville J, Collins D, **Moore LSP**, Dheansa B, Jenkins ATA, Booth SP, Agha R, Shah M, Young AER. Protocol for the development of a Core Indicator Set for reporting burn wound infection in trials: The ICon-B study. *BMJ Open.* 2019; 9:e026056. PMID:31092650.
- 2019 Heard KL, Hughes S, Mughal N, Azadian BS, **Moore LSP**. Evaluating the impact of the ICNET® clinical decision support system for antimicrobial stewardship. *Antimicrob Resist Infect Contr.* 2019;8:51. PMID: 30886704.
- 2019 Hughes SJ, **Moore LSP**. Antimicrobial stewardship. *B J Hosp Med.* 2019;80(3):C42-C45. PMID:30860917.
- 2019 Rabinowicz S, O'Hare M, **Moore LSP**, Mughal N. Xpert MRSA screening in surgical patient flow; time for a rethink for hub-and-spoke laboratory models? *J Med Micro.* 2019;68(3):290-291. PMID:30628880.
- 2019 Rawson TM, Hernandez B, **Moore LSP**, Blandy O, Herrero P, Gilchrist MC, Gordon A, Toumazou C, Sriskandan S, Georgiou P, Holmes AH. Supervised machine learning for the prediction of infection on admission to hospital: a prospective observational cohort study. *J Antimicrob Chemother.* 2019;74(4):1108-1115. PMID:30590545.
- 2018 Abdolrasouli A, Petrou MA, Park H, Rhodes JL, Rawson TM, **Moore LSP**, Donaldson H, Holmes AH, Fisher MC, Armstrong-James D. Detection of TR34/L98H cyp51A mutation in Aspergillus fumigatus: A 17 year laboratory based surveillance of clinical isolates from a centralized diagnostic mycology service in London, United Kingdom. *Front Microbiol.* 2018;9:2234. PMID:30294314.
- * 2018 Knight GM, Costelloe C, Deeny S, **Moore LSP**, Hopkins S, Johnson AP, Robotham J, Holmes AH. A first step to quantifying where acquisition of antibiotic resistance occurs: A mathematical modelling study. *BMC Medicine.* 2018;16(1):137. PMID:30134939.
- 2018 Welman T, McKean AR, Duggan E, Rahman SM, **Moore LSP**, Horwitz M. Tetanus 'Quick Stik'-is the NHS missing a trick? *Injury.* 2018;49(6):1240-1241. PMID: 29685702.
- 2018 McNeal P, Rahman S, **Moore LSP**, McKean AR, Atkins J. Rapid microbial diagnosis in burns patients: Time for a change? *Burns.* 2018;44(4):1020-1021. PMID:29544704.
- 2018 Rawson TM, Charani E, **Moore LSP**, Gilchrist M, Georgiou P, Hope W, Holmes AH. Exploring use of C-reactive protein to estimate the pharmacodynamics of vancomycin. *Ther Drug Monit.* 2018;40(3):315-321. PMID:29561305.
- 2018 Dagens AB, Mughal N, Sisson A, **Moore LSP**. Experience of using beta-d-glucan assays in the intensive care unit, *Critical Care.* 2018;22(1):125. PMID:29751822.
- 2018 McKean AR, Aggarwal D, Torres-Grau J, Welman T, **Moore LSP**, Jones I. Is flucloxacillin monotherapy sufficient for the treatment of skin and soft tissue infections in plastic surgery? *J Plast Reconstr Aesthet Surg.* 2018;71(6):919-920. PMID:29477266.

- 2018 Rudd E, Francis N, **Moore LSP**, Fearfield L. An erythematous papular rash on the left flank of a 31-year-old woman: A quiz. *Acta Derm Venereol.* 2018; ;98(4):477-478. PMID:29327062.
- 2018 Rawson TM, **Moore LSP**, Castro-Sánchez E, Charani E, Hernandez B, Alividza V, Husson F, Toumazou C, Ahmed R, Georgiou P, Holmes AH. Development of a patient-centred intervention to improve knowledge and understanding of antibiotic therapy in secondary care. *Antimicrob Resist Infect Contr.* 2018;7:43. PMID:29568516.
- 2018 Rawson TM, O'Hare D, Herrero P, Sharma S, **Moore LSP**, De Barra E, Roberts JA, Gordon A, Hope W, Georgiou P, Cass AEG, Holmes AH. Delivering precision antimicrobial therapy through closed-loop control systems. *J Antimicrob Chemother.* 2018;73(4):835-843. PMID:29211877.
- 2018 Rawson TM, Castro-Sánchez E, Charani E, **Moore LSP**, Holmes AH, Ahmad R. Involving citizens in priority setting for public health research: implementation in infection research. *Health Expectations.* 2018;21(1):222-229. PMID:28732138.
- 2017 Herrero P, Rawson TM, Philip A, **Moore LSP**, Holmes AH, Georgiou P. Closed-loop control for precision antimicrobial delivery: An in silico proof-of-concept. *IEEE Trans Biomed Eng.* 2017;99:1.
- 2017 Hernandez B, Rawson TM, **Moore LSP**, Evans B, Toumazou C, Holmes AH, Georgiou P. Supervised learning for infection risk inference using pathology data. *BMC Medical Informatics and Decision Making.* 2017;17(1):168. PMID:29216923
- 2017 Eades C, Hughes S, Heard KL, **Moore LSP**. Antimicrobial therapies for Gram-positive infections. *Clin Pharmacist.* 2017;9(9):Online.
- 2017 Boyd SE, **Moore LSP**, Rawson TM, Holmes AH. Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al impact on resistance remains unclear. *Lancet Infect Dis.* 2017;17(9):899-900. PMID:28845792.
- * 2017 Rawson TM, **Moore LSP**, Hernandez B, Charani E, Castro-Sánchez E, Herrero-Vinas P, Hayhoe B, Hope W, Georgiou P, Holmes AH. A systemic review of infection related clinical decision support systems across patient pathways: Are we failing to investigate these interventions appropriately? *Clin Microbiol Infect.* 2017; 23(8):524-532. PMID:28268133.
- 2017 Birgand G, Troughton R, **Moore LSP**, Castro-Sánchez E, Charani E, Rawson TM, Holmes AH. Blogging in infectious diseases and clinical microbiology: Assessment of the 'blogosphere' content. *Infect Contr Hosp Epidemiol.* 2017;38(7):832-839. PMID:28516820.
- 2017 Charani E, Gharbi M, **Moore LSP**, Castro-Sánchez E, Lawson W, Gilchrist M, Holmes AH. Effect of Adding a mHealth Intervention to a Multimodal Antimicrobial Stewardship Programme Across Three Teaching Hospitals – An Interrupted Time Series Study. *J Antimicrob Chemother.* 2017;72(6):1825-1831. PMID:28333297.
- 2017 Boyd SE, **Moore LSP**, Gilchrist MJ, Costelloe C, Castro-Sánchez E, Dean Franklin B, Holmes AH. Obtaining antibiotics online from within the UK: a cross-sectional study. *J Antimicrob Chemother.* 2017;72(5):1521-1528. PMID:28333179.
- 2017 Vella V, Aylin PP, **Moore LSP**, King A, Naylor NR, Birgand GJC, Lishman H, Holmes AH. Bed utilisation and increased risk of Clostridium difficile infections in acute hospitals in England 2013/14. *BMJ Qual Saf.* 2016;26(6):460-465. PMID:27601687.
- 2017 Geoghegan O, Eades C, **Moore LSP**, Gilchrist MJ. Clostridium difficile: diagnosis & treatment update. *Clin Pharmacist.* 2017;9(2):Online.
- 2017 Rawson TM, Charani E, **Moore LSP**, Hererro-Vinas P, Baik JS, Philip A, Gilchrist M, Brannigan E, Georgiou P, Hope W, Holmes AH. Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. *J Infect.* 2017;74(3):320-324. PMID:28043826.
- 2017 Rawson TM, **Moore LSP**, Tivey A, Tsao A, Gilchrist MJ, Charani E, Holmes AH. Behaviour change interventions to influence antimicrobial prescribing: A cross-sectional analysis of reports from UK state-of-the-art scientific conferences. *Antimicrob Resist Infect Cont.* 2017;6:11. PMID:28101333
- 2017 Rawson TM, **Moore LSP**, Gill DPS, Lupton MGF, Holmes AH. Promoting medical student engagement with antimicrobial stewardship through involvement in undergraduate research. *J Infection.* 2017;74(2):200-202. PMID:27620991.
- 2016 Rawson TM, Butters TP, **Moore LSP**, Castro-Sánchez E, Cooke FJ, Holmes AH. Exploring the coverage of antimicrobial stewardship across UK clinical postgraduate training curricula. *J Antimicrob Chemother.* 2016;71(11):3284-3292. PMID:27432603.
- 2016 Rawson TM, Charani E, **Moore LSP**, Hernandez B, Castro-Sánchez E, Herrero-Vinas P, Georgiou P, Holmes AH. Mapping the decision pathways of acute infection management in secondary care among UK medical physicians: A qualitative study. *BMC Medicine.* 2016;14(1):208-218. PMID:27938372.
- 2016 Rawson TM, **Moore LSP**, Hernandez-Perez B, Castro-Sánchez E, Charani E, Ahmad R, Holmes AH. Patient engagement with infection management in secondary care: A qualitative investigation of current experiences. *BMJ Open.* 2016;6:e011040. PMID:27799238.
- 2016 Vella V, **Moore LSP**, Robotham JV, Davies F, Birgand GJC, Otter JA, Brannigan E, Dyakova E, Knight GM, Mookerjee S, Holmes AH. Isolation demand from carbapenemase-producing Enterobacteriaceae screening strategies based on a West London hospital network. *J Hosp Infect.* 2016;94(2):118-24. PMID:27209055.
- 2016 Castro-Sánchez E, **Moore LSP**, Husson F, Holmes AH. What are the factors driving antimicrobial resistance? Perspectives from a public event in London, England. *BMC Infect Dis.* 2016;16(1):465. PMID:27590053.

- 2016 Gharbi M, **Moore LSP**, Castro-Sánchez E, Spanoudaki E, Grady C, Holmes AH, Drumright LN. A needs assessment study for optimising prescribing practice in secondary care junior doctors: The Antibiotic Prescribing Education among Doctors (APED) Study. *BMC Infect Dis.* 2016;16(1):456. PMID:27576784.
- 2016 Rawson TM, **Moore LSP**, Holmes AH. Amoxicillin for severe acute malnutrition in children. *N Engl J Med.* 2016;375:190-191. PMID:27410939.
- * 2016 Gill S, Hui K, Farne H, Garnett J, Baines D, **Moore LSP**, Holmes AH, Filloux A, Tregoning J. Increased airway glucose increases airway bacterial load in hyperglycaemia. *Nat Sci Rep.* 2016;6:27636. PMID:27273266.
- 2016 Micallef C, McLeod M, Castro-Sánchez E, Gharbi M, Charani E, **Moore LSP**, Gilchrist M, Husson F, Costelloe C, Holmes AH. Investigating the need for an evidence-based antimicrobial stewardship smartphone app for the general public across healthcare settings. *JMIR Mhealth Uhealth.* 2016;4(3):e83. PMID:27383743.
- 2016 Boyd S, Rawson TM, **Moore LSP**, Holmes AH. Preventing bloodstream infections in children: What's the CATCH? *Lancet.* 2016;388(10043):462–463. PMID:27507755.
- 2016 **Moore LSP**, Cunningham J, Donaldson H. A clinical approach to *Pseudomonas aeruginosa*. *Br J Hosp Med.* 2016;77(4):C50-54. PMID:27071439.
- 2016 Birgand GJC, **Moore LSP**, Bourigault C, Vella V, Lepelletier D, Holmes AH, Lucet JC. Measures to eradicate multi-drug resistant organism outbreaks: How much does it cost? *Clin Microb Infect.* 2016;22(2):162e1-9. PMID:26482264.
- 2016 Rawson TM, **Moore LSP**, Hatcher JC, Donaldson H, Holmes AH. Plasmid-mediated colistin resistance mechanisms: is it time to revise our approach to selective digestive decontamination? *Lancet Infect Dis.* 2016;16(2):149-50. PMID:26867455.
- 2016 Rawson TM, **Moore LSP**, Gilchrist MG, Holmes AH. Antimicrobial stewardship; are we failing in cross-specialty clinical engagement? *J Antimicrob Chemother.* 2016;71(2):554-9. PMID:26498747.
- * 2016 **Moore LSP**, Owens DS, Jepson A, Turton JF, Ashworth S, Donaldson H, Holmes AH. Waterborne *Elizabethkingia meningoseptica* in adult critical care. *Emerg Infect Dis.* 2016;22(1):9-17. PMID:26690562.
- * 2016 Ardal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, Cohn J, Pittet D, Daulaire N, Morel C, Rizvi Z, Balasegaram M, Dar O, Heymann D, Holmes AH, **Moore LSP**, Laxminarayan R, Mendelson M, Röttingen JA. International cooperation to improve access to and sustain effectiveness of antimicrobials. *Lancet.* 2016;387(10015):296-307. PMID:26603920.
- * 2016 Holmes AH, **Moore LSP**, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJV. Understanding the mechanisms and the drivers of antimicrobial resistance. *Lancet.* 2016;387(10015):176-187. PMID:26603922.
- 2015 Vella V, Gharbi M, **Moore LSP**, Robotham J, Davies F, Brannigan E, Galletly T, Holmes AH. Screening suspected cases for carbapenemase-producing Enterobacteriaceae; inclusion criteria and demand. *J Infection.* 2015;71(4):493-5. PMID:26070742.
- * 2015 **Moore LSP**, Leslie A, Meltzer M, Sandison A, Efstratiou A, Sriskandan S. *Corynebacterium ulcerans* cutaneous diphtheria. *Lancet Infect Dis.* 2015;15(9):1100-7. PMID:26189434.
- 2015 Gharbi M, **Moore LSP**, Gilchrist M, Thomas CP, Bamford K, Brannigan ET, Holmes AH. Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48 producing *Klebsiella pneumoniae* outbreak in a London renal unit. *Int J Antimicrob Agent.* 2015;46(2):150-6. PMID:25979640.
- 2015 Jones P, **Moore LSP**, Donaldson H. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 3 year London experience. *Am J Infect Control.* 2015;43(4):419-420. PMID:25690875.
- 2015 Freeman R, **Moore LSP**, Charlett A, Donaldson H, Holmes AH. Exploring the epidemiology of carbapenem resistant Gram-negative bacteria in West London and the utility of routinely collected hospital microbiology data. *J Antimicrob Chemother.* 2015; 70(4):1212-8. PMID:25525198.
- * 2014 **Moore LSP**, Freeman R, Gilchrist M, Gharbi M, Brannigan ET, Donaldson H, Livermore DM, Holmes AH. Homogeneity of antimicrobial policy, yet heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility among 108,717 clinical isolates from primary, secondary and tertiary care patients in London. *J Antimicrob Chemother.* 2014;69(12):3409-22. PMID:25118270.
- 2014 **Moore LSP**, Moore M, Sriskandan S. Ebola and other viral haemorrhagic fevers: a local operational approach. *Br J Hosp Med.* 2014;75(9):515-522. PMID:25216168.
- 2014 Charani E, Castro-Sánchez E, **Moore LSP**, Holmes AH. Do smartphone applications in healthcare require a governance and legal framework? It depends on the application. *BMC Medicine.* 2014;12:29. PMID:24524344.
- 2014 King C, Aylin P, **Moore LSP**, Pavlu J, Holmes AH. Syndromic surveillance of surgical site infections –a case study in coronary artery bypass graft patients. *J Infection.* 2014;68(1):23-31. PMID:24001609.
- 2014 **Moore LSP**, Clarke IL, Donaldson H, Azadian B. Community-acquired *Klebsiella pneumoniae* liver abscess: the London experience. *Infection.* 2014;42(1):219-21. PMID:23990158.
- 2013 Thomas CP, **Moore LSP**, Elamin N, Doumith M, Zhang J, Maharjan S, Warner M, Perry C, Turton JF, Johnstone C, Jepson A, Duncan NDC, Holmes AH, Livermore DM, Woodford N. Early (2008-10) hospital outbreak of *Klebsiella pneumoniae* OXA-48 carbapenemase in the UK. *Int J Antimicrob Agent.* 2013;42(6):531-6. PMID:24207018.
- 2013 **Moore LSP**, Donaldson H. Investigating *Clostridium difficile*. *Br J Hosp Med.* 2013;74(10):C146-149. PMID:24273764
- 2013 Gilchrist M, **Moore LSP**, Thomas CP, Brannigan ET. Daptomycin & Warfarin. *Br J Clin Pharmacy.* 2013;7:1.
- 2013 Freeman R, **Moore LSP**, Garcia-Alvarez L, Charlett A, Holmes AH. Advances in electronic surveillance for healthcare-associated infections in the 21st century: a systematic review. *J Hosp Infect.* 2013;84(2):106-119. PMID:23648216.

- 2013 Charani E, Kyratsis Y, Lawson W, Wickens H, Brannigan ET, **Moore LSP**, Holmes AH. An analysis of the development and implementation of a Smartphone Application for the delivery of Antimicrobial Prescribing Policy: Lessons Learnt. *J Antimicrob Chemother*. 2013;68(4):960-967. PMID:23258314.
- 2012 King C, Garcia Alvarez L, Holmes AH, **Moore LSP**, Galletly T, Aylin P. Risk factors for healthcare-associated urinary tract infection and their applications in surveillance using hospital administrative data: a systematic review. *J Hosp Infect*. 2012;82(4):219-226. PMID:22704636.
- 2012 **Moore LSP**, Cooley N, Gilchrist M. Clostridium difficile-microbiology & infection. *Clin Pharmacist*. 2012;4:250-254.
- 2012 Gilchrist M, Cooley N, **Moore LSP**. Clostridium difficile-managing infections. *Clin Pharmacist*. 2012;4:257-261.
- 2012 **Moore LSP**, Hatcher J, Donaldson H. Using infection specialists. *Br J Hosp Med*. 2012;73(7):109-11. PMID:22875398.
- 2012 Morris TC, **Moore LSP**, Shaunak S. Doctors taking a pulse using their mobile phone can spread MRSA. *Brit Med J*. 2012;344:e412. PMID:22252697.
- 2011 **Moore LSP**, Chiodini PL. Clinical feature-tropical helminths. *Africa Health*. 2011;34(1):30-35.
- 2011 Lee YJ, **Moore LSP**, Almyeda J. A report on a rare case of Klebsiella ozaenae causing atrophic rhinitis in the United Kingdom. *BMJ Case Rep*. 2011;pii:bcr0920114812. PMID:22669526.
- 2010 **Moore LSP**, Chiodini PL. Tropical helminths. *Medicine*. 2010;38(1):47-51.

WORK GROUP JOURNAL ARTICLES

- 2022 Enne VI, Aydin A, Baldan R, **INHALE WP1 Study Group**, et al. Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. *Thorax*. 2022;[InPress].
- 2022 Kousathanas A, Pairo-Castineira E, Rawlik K, **GenOMICC investigators**, et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. *Nature*. 2022;607(7917):97-103.

BOOKS

- 2019 **Moore LSP**, Hatcher JC. Infectious Diseases, Microbiology and Virology: A Q&A Approach for Specialist Medical Trainees. Cambridge University Press; 2019. ISBN: 9781316609712.
- 2019 Lewis H, Menon R, **Moore, LSP**, Grennhal G, Stockton K. MRCP Part 2: 450 Best Of Fives. Second Edition. JP Medical Publishing; 2019. ISBN: 9781909836846.
- 2013 Allen C, Forbes S, Hunt D, Lewis H, Menon R, **Moore LSP**. MRCP Part 2: 450 Best Of Fives. JP Medical Publishing; 2013. ISBN: 9781907816451.

BOOK CHAPTERS

- 2019 **Moore LSP**. Infectious Diseases; **Moore LSP**, Emergencies in HIV positive patients. In: Ramrakha P, Moore K, Sam AH. The Oxford Handbook of Acute Medicine 4th Edition. Oxford University Press; 2019. ISBN: 9780198797425.
- 2015 **Moore LSP**. Intensive care. In: Warren O, Dean-Franklin B, Vincent C, editors. Going into Hospital? A Guide for Patients, Carers and Families. Eastdown Publishing; 2015. ISBN: 9780993312205.
- 2014 Castro-Sánchez E, Charani E, **Moore LSP**, Gharbi M, Holmes AH. "On call: antibiotics"- development and evaluation of a serious antimicrobial prescribing game for hospital care. In: Games for Health 2014. Editors: Schouten B, Fedtke S, Schijven M, Vosmeer M, Gekker A. Springer Vieweg; 2014. ISBN: 9783658071400.
- 2014 **Moore LSP**, Schelenz S. Candida Infection in the Intensive Care Unit. In: Arnold A, Griffin G, editors. Challenging Concepts in Infectious Diseases & Clinical Microbiology. Oxford University Press; 2014. ISBN: 9780199665754.
- 2014 **Moore LSP**. Biomedical engineering solutions for antimicrobial resistance: a two-pronged attack. In: Toumazou C, editor. Centre for Bio-Inspired Technology Annual Report. Imperial College London; 2014.
- 2011 **Moore LSP**, Moore M, Almeida B. Higher Degrees, Diplomas & Certificates. In: Smith P, Nijjer S, Gill J, Levy J, editors. Secrets of Success – Academic Medicine. Hodder Arnold Press Ltd; 2011. ISBN: 9781853159572.
- 2009 **Moore LSP**. Infectious Diseases & Medical Microbiology; **Moore LSP**. Core Medical Training; **Moore LSP**. Acute Care; **Moore LSP**. Academic Achievement. In: Gladwell M, Ramachandran M, Smith P, editors. Secrets of Success – Getting into Specialty Training. Royal Society of Medicine Press; 2009. ISBN: 9781853158933.

INVITED LECTURES

- 2022 The role of diagnostics in antimicrobial stewardship. *WHO S.E.Asia Regional Office.*
2022 Innovating COVID-19 Approaches for a sustainable Future. *27th World Organization of Family Doctors, London.*
2022 Monkeypox: a new clinical and IPC challenge. *Healthcare Infection Society, UK.*
2022 Current therapeutic options for carbapenem resistant Enterobacteriales. *32nd ECCMID, Lisbon.*
2022 Physician decisions when managing patients with HAP/VAP. *41st Int Symp Intensive Care & Emerg Med, Brussels.*
2022 The impact of COVID-19 on antimicrobial stewardship. *Japanese Soc Clin Micro, Sendai.*
2021 Challenging cases in critical care. *Brit Soc Antimicrob Chemother, UK.*
2021 Difficult-to-treat resistant Pseudomonas aeruginosa in the ICU. *Federation of Infection Societies, UK.*
2021 Difficult-to-treat resistant Pseudomonas aeruginosa in the ICU. *Crit Care & Antimicrob Resist, Netherlands.*
2021 Antimicrobial Resistance after COVID-19 – what challenges await? *Patient Safety 2020, Dubai.*
2021 Difficult-to-treat resistant Pseudomonas aeruginosa in the ICU. *40th Int Symp Intensive Care & Emerg Med, Global.*
2021 Vaccinating adults & high risk cohorts. *Vaccines Summit, Jordan.*
2021 Changing priorities in diagnostic stewardship. *Pakistan.*
2021 The double-edged sword of COVID-19 on antimicrobials and antimicrobial resistance. *31st ECCMID, Global.*
2021 Sharing best practices in the management of MDR-Pseudomonas. *4th Int. Conf. on AMR, United Arab Emirates.*
2020 Is antimicrobial stewardship at risk in the face of COVID-19? *bioMérieux, Global.*
2020 COVID-19 Winter planning. *Healthcare Infection Society, UK.*
2020 New antimicrobials for resistant Gram negative infections. *Middle East & North Africa infection summit, Jordan.*
2020 Unanticipated consequences of COVID-19. *Healthcare Infection Society, UK.*
2019 Urosepsis: optimising early management. *Stamp out sepsis, Leeds.*
2019 De-implementing antimicrobial stewardship. *International Conference of Prevention & Infection Control, Geneva.*
2019 Technological solutions to support infection management. *Antimicrobial research collaborative, London.*
2019 Surveillance to stewardship: bridging gap in critical care. *London intensive care group.*
2019 Interventions for healthcare associated infections. *Middle East & North Africa infection summit, Jordan.*
2018 Global trends in antimicrobial resistance. *Middle East & North Africa antimicrobial resistance summit, Jordan.*
2018 Urinary tract infections in the age of multi-drug resistance. *Stamp out sepsis, Leeds.*
2018 Standardising infection control for burns in the UK. *Burn injury management, London.*
2017 Infections in burns patients. *25th Magill symposium, London*
2016 Technology & diagnostics in antimicrobial prescribing. *6th Journée antibio-résistance & infections, Paris.*
2016 Antimicrobial resistance & immunosuppression. *4th Global perioperative cancer care conference, London.*
2016 Surveillance to stewardship: bridging the gap in critical care. *Assoc. anaesthetists Great Britain & Ireland, London.*
2016 Surveillance to stewardship: bridging the gap in one health. *Responsible use of antibiotics in animals, The Hague.*
2015 Innovation to Support Antibiotic Prescribing in Acute Care. *Antimicrobial research collaborative, London.*
2014 Surveillance to stewardship: bridging the gap in drug development. *Global health: Drug resistance, London.*
2013 Increasingly complex antimicrobial resistance in critical care. *British infection society, London.*
2013 Central nervous system infections in the emergency department. *Royal society of medicine, London.*

PUBLISHED ABSTRACTS

- 2022 Pallett SJ, Rayment M, Randell P, Davies GW, **Moore LSP**. Early identification of high-risk individuals for combination monoclonal antibody therapy is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay. *BMJ Mil Health* 2022;168:e1.
2021 Pallett SJC, Jones R, Rayment M, Pallett M, Mughal N, Rosadas de Oliveira C, Randell P, Davies GW, Tedder R, McClure MO, O'Shea MK, **Moore LSP**. Clinical implications of the differential antibody response in mild-moderate SARS-CoV-2: a prospective multi-centre cross-sectional study. *BMJ Mil Health*. 2021;167:e1.
2021 Low R, Young K, Verani L, Cotton DT, Welman T, **Moore LSP**, Horwitz MD. Point of care testing for tetanus immunity: a systematic review. *B J Surg*. 2021;108(2): znab134.448.
2018 Hernandez B, Herrero P, Rawson TM, **Moore LSP**, Toumazou C, Holmes AH, Georgiou P. Enhancing antimicrobial surveillance: an automated, dynamic and interactive approach. *Int J Infect Dis*. 2018;73(S1):122
2018 Bull L, Tittle V, Hughes S, Skene H, **Moore LSP**, Mughal N, Nelson M, Jones R, Rayment M. Exploring the epidemiology and management of shigellosis in a large acute hospital trust. *HIV Medicine*. 2018;19(S2):S9.
2017 Hernandez B, Herrero P, Rawson TM, **Moore LSP**, Charani E, Holmes AH, Georgiou P. Data-driven web-based intelligent decision support system for infection management at point-of-care. In: Proceedings of the 10th Int. Conf. on Biomedical Engineering Systems and Technologies. *HEALTHINF*. 2017;5:119-127. ISBN: 9789897582134
2016 **Moore LSP**, Freeman R, Charlett A, Otter JA, Donaldson H, Holmes AH. Real time antimicrobial resistance surveillance in critical care: identifying outbreaks of carbapenem resistant Gram negative bacteria from routinely collected data. *Int J Infect Dis*. 2016;45(S1):211.
2015 Turnbull AJ, **Moore LSP**, Azadian BS. To PPE or not to PPE. *J Infect Prevent*. 2015;16(S1):S13-14.
2014 **Moore LSP**, Charani E, Herrero-Vinas P, Georgiou P, Hernandez B, Holmes AH. Case-Based Reasoning for Antimicrobial Prescribing Decision Support: A Solution for Critical Care? In: Medical Engineering Centres Annual Meeting & Bioengineering14. Editors: Stevens-Smith J. *MECbioeng*. 2014. ISBN: 9780993039003.

- 2014 Owens DS, **Moore LSP**, Johnstone C, Turton JF, Donaldson H, Jepson A, Holmes AH. Prolonged critical care Elizabethkingia meningoseptica outbreak in a UK teaching hospital. *Intensive Care Med.* 2014;40(S1):S98-99.
- 2014 McLeod M, Gharbi M, Charani E, Castro-Sánchez E, **Moore LSP**, Gilchrist M, Holmes AH. Is there a role for using mobile device applications to support antimicrobial stewardship? Preliminary findings from a survey of general practitioners in the United Kingdom. *Int J Pharm Pract.* 2014;22(S2):71-72. PMID: 25163603.
- 2014 **Moore LSP**, Charani E, Murthy K, Herrero-Vinas P, Georgiou P, Hatzaras K, Holmes AH. Infection management in critical care- point of care decision support system. *ESCMID Lecture Library.* 2014;R717.
- 2014 Castro-Sánchez E, Charani E, **Moore LSP**, Gharbi M, Holmes AH. Taking antimicrobial stewardship initiatives to the next level: Development of a serious prescribing game for acute care. *Int J Infect Dis.* 2014;21(S1):21.005.
- 2014 Gharbi M, Gilchrist M, **Moore LSP**, Brannigan ET, Bamford K, Holmes AH. Development of an early warning system for carbapenem resistance derived from an OXA-48 K. pneumoniae outbreak. *Int J Infect Dis.* 2014;21(S1):97.
- 2013 **Moore LSP**, Donaldson H, Thomas CP, Brannigan E, Holmes AH. Investigating increasingly complex resistance in Enterobacteriaceae & Pseudomonas aeruginosa in critical care. *J Infect.* 2013;67(4):347.
- 2012 **Moore LSP**, Thomas CP, Brannigan ET, Holmes AH. Antimicrobial resistance prevalence at the first UK Academic Health Sciences Centre. *Clin Microbiol Infect.* 2012;18(S3):306. PMID:22493782.
- 2012 Charani E, Lawson W, Wickens H, Mookerjee S, **Moore LSP**, Jacklin A, Main J, Holmes AH. Imperial antimicrobial prescribing policy: harnessing smart-phone technology to develop a clinical decision support application. *Clin Microbiol Infect.* 2012;18(S3):608. PMID: 22493782.
- 2012 **Moore LSP**, Barnass SJ, Kyi M. Quantitative adenosine tri-phosphate detection to aid infection control. *Clin Microbiol Infect.* 2012;18(S3):808. PMID: 22493782.
- 2010 **Moore LSP**, Mughal N, Demertzis E, Azadian BS. Reducing paediatric blood culture contaminants. *Clin Microbiol Infect.* 2010;16(S2):682. PMID: 20412063.

CONFERENCE PROCEEDINGS

- 2022 Chan MS, Holloway R, Polya R, Sloan R, Kowalik JC, Ashfield T, **Moore LSP**, et al. The benefits that a novel antimicrobial provides when viewed from an insurance value perspective. ISPOR 2022
- 2022 Mistry R, Rawson TM, Troise O, Mughal N, **Moore LSP**, et al. Comparison of haematological and hepatic events from standard & high dose ceftriaxone: a retrospective observational study. *Federation of Infection Societies.*
- 2022 Charani E, Mendelson M, Ahmad R, Mpundu M, Mbamalu O, Bonaconsa C, Singh S, Peiffer-Smadja N, Pallett SJC, Anton Vazquez V, **Moore LSP** et al. National action plans for antimicrobial resistance: a framework for operationalising existing plans and developing a research strategy to address gaps and opportunities. *32nd ECCMID, Lisbon.*
- 2022 Hughes S, Troise O, Deol P, Mughal N, **Moore LSP**. Alternative antimicrobial stewardship interventions can impact breadth of spectrum but not volume of antibacterials in UK emergency departments; an analysis of two London teaching hospitals over 5 years. *32nd ECCMID, Lisbon.*
- 2021 Rawson TM, Brzeska-Trafny I, Maxfield R, Almeida M, Gilchrist M, Gonzalo X, **Moore LSP**, et al. Ceftazidime-avibactam and aztreonam synergy testing: development of a practical laboratory approach using an E-test/disc method. *Federation of Infection Societies.*
- 2021 Ranganathan N, Zheng C, Ferran E, Randell P, **Moore LSP**, et al. Evaluating inactivation media for BioFire® RP2.1+ testing for biosafety. *31st ECCMID, Virtual.*
- 2020 Lamb G, Kingston H, Mughal N, **Moore LSP**. Comparison of PCR-detected bacterial gastroenteritis cases with their clinical phenotypes: are we overestimating incidence in hospitalised patients? *Federation of Infection Societies.*
- 2020 Taylor R, Heard K, Hughes S, Bartholomew B, Mughal N, **Moore LSP**. Assessing outpatient parenteral antimicrobial therapy for the treatment of intra-abdominal collections. *Federation of Infection Societies.*
- 2020 Rela M, Opel S, Williams S, Collins D, Martin K, Mughal N, **Moore LSP**. Operating room fomites as potential sources for microbial transmission in burns theatres. *Federation of Infection Societies.*
- 2020 Hughes S, Heard K, Mughal N, **Moore LSP**. The role of antimicrobial dosing in patients with sepsis-induced acute kidney injury; a single centre observational study. *Federation of Infection Societies.*
- 2020 Killington K, **Moore LSP**, et al. Temocillin 4g or 6g? Breakpoints vs Practise. *Federation of Infection Societies.*
- 2019 Rajput J, **Moore LSP**, et al. Predicting Cotrimoxazole-Associated Acute Kidney Injury and Hyperkalaemia. *Federation of Infection Societies, Edinburgh.*
- 2019 Hughes S, Davidson A, **Moore LSP**, et al. Group B Streptococcus bacteraemia in mum and newborn following antimicrobial prophylaxis: to screen or not to screen? *Federation of Infection Societies, Edinburgh.*
- 2019 Davidson A, Hughes S, Mughal S, **Moore LSP**. Streptococcus agalactiae macrolide/lincosamide resistance; implications for puerperal antimicrobial therapy. *Federation of Infection Societies, Edinburgh.*
- 2019 Lowe A, Sarian A, Gibbani M, Russell K, **Moore LSP**, et al. Carbapenem resistant organisms- To screen or not to screen? *Federation of Infection Societies, Edinburgh.*
- 2019 Welman T, Carroll N, McKean A, Rahman S, **Moore LSP**, et al. Tetanus Quick Stik – is the NHS missing a trick? *14th International Federation of Societies for Surgery of the Hand Congress, Berlin.*
- 2019 McKean A, Assiotis A, Hassan A, Elvey M, **Moore LSP**, et al. Propionibacterium acnes infection in the native wrist joint. *14th International Federation of Societies for Surgery of the Hand Congress, Berlin.*

- 2019 Ark R, Mandalia S, **Moore LSP**, et al. Evaluating the long-term impact of antimicrobial stewardship in intensive care. *29th ECCMID, Amsterdam*.
- 2019 Saleh M, Ebrahimsa M, Mughal N, **Moore LSP**. Helminth serology testing pathways could make significant savings in non-endemic settings. *29th ECCMID, Amsterdam*.
- 2019 Aggarwal D, Mughal N, Kearns A, **Moore LSP**. Antimicrobial resistance and genetic diversity of Panton-Valentine leukocidin-positive *S. aureus*. *29th ECCMID, Amsterdam*.
- 2018 Lewis K, Ebrahimsa MU, Pallett S, Mughal N, **Moore LSP**. Investigation and initial management of suspected MERS in patients at Chelsea and Westminster Hospital. *Federation of Infection Societies, Gateshead*.
- 2018 Bhardwaj Shah A, Ebrahimsa MU, Pallett S, Mughal N, **Moore LSP**. Investigating the Utilisation of Rare and Imported Pathogens Laboratory Testing. *Federation of Infection Societies, Gateshead*.
- 2018 Hurt W, Elliott J, Randell P, **Moore LSP**. Evaluating the clinical efficacy of weekend flu testing. *Federation of Infection Societies, Gateshead*.
- 2018 Elias J, Lall K, Lamont H, Hughes S, **Moore LSP**, et al. Antimicrobial stewardship for HAP. *Federation of Infection Societies, Gateshead*.
- 2018 Heard K, Hughes S, Mughal N, **Moore LSP**. Safety and efficacy of Temocillin. *Federation of Infection Societies, Gateshead*.
- 2018 Singh S, Mughal N, **Moore LSP**. Clinical utility of beta-D-glucan. *Federation of Infection Societies, Gateshead*.
- 2018 Hughes S, Pallett S, Mughal N, **Moore LSP**. Evaluation of the Alere BinaxNOW® pneumococcal urinary antigen. *Federation of Infection Societies, Gateshead*.
- 2018 Kanitkar T, Heard K, Aggarwal D, Mughal N, **Moore LSP**. Assessing the safety and cost-effectiveness of upper limb cellulitis OPAT. *Federation of Infection Societies, Gateshead*.
- 2018 Chin H, Hughes S, Heard K, Mughal N, **Moore LSP**. Once daily dosing of Tigecycline for OPAT. *Federation of Infection Societies, Gateshead*.
- 2018 Rawson TM, Hernandez B, Blandy O, **Moore LSP**, et al. Supervised machine learning for the prediction of bacteraemia using routinely collected blood science data. *28th ECCMID, Madrid*.
- 2018 Rawson TM, **Moore LSP**, et al. Patient engagement with antimicrobial decision making in secondary care: a co-designed pilot intervention. *28th ECCMID, Madrid*.
- 2018 Rawson TM, Hernandez B, Blandy O, **Moore LSP**, et al. Case based reasoning for individualized antimicrobial selection: can intelligent decision support improve antimicrobial management. *28th ECCMID, Madrid*.
- 2018 Marks M, Ross J, Jones I, **Moore LSP**, Collins D. Characterising toxic shock syndrome among paediatric burns patients. *28th European Congress of Clinical Microbiology & Infectious Diseases, Madrid*.
- 2018 Hughes S, Heard K, Mughal N, **Moore LSP**. Evaluating the impact of an antimicrobial stewardship programme in secondary care across multiple indicators. *28th ECCMID, Madrid*.
- 2018 Narouz M, Aggarwal D, **Moore LSP**, et al. Evaluating the additional yield and cost-effectiveness of 16S rRNA testing. *28th ECCMID, Madrid*.
- 2018 Lee A, Rawson TM, **Moore LSP**. Management of ophthalmic infections across care pathways in London, UK. *28th ECCMID, Madrid*.
- 2018 Rabinowicz S, O'Hare M, **Moore LSP**, et al. Evaluating the utility of MRSA PCR in surgical patient flow; time for a rethink for hub-and-spoke laboratory models. *21st British Infection Association Annual Meeting, London*.
- 2018 Shah MM, Deol P, **Moore LSP** et al. Improving infection control in the use of ultrasound equipment in the emergency department. *14th World Congress on Ultrasound in Emergency and Critical Care, Madrid*.
- 2017 Char A, Heard KL, Mughal N, Bartholomew B, **Moore LSP**. Exploring appropriate utilisation of ambulatory care for pyelonephritis. *Federation of Infection Societies, Birmingham*.
- 2017 El-Koubani O, Mughal N, Abani O, **Moore LSP**. Adequate treatment guidelines for *Pseudomonas aeruginosa* bacteraemia. *Federation of Infection Societies, Birmingham*.
- 2017 Shah M, Deol P, Mughal N, **Moore LSP**. Improving infection control in the use of ultrasound equipment in the emergency department. *Federation of Infection Societies, Birmingham*.
- 2017 Aggarwal D, Patvi F, Mughal N, **Moore LSP**. Evaluating Panton Valentine Leukocidin testing practices, prevalence and geographical distribution in North West London. *Federation of Infection Societies, Birmingham*.
- 2017 Dagens A, Sisson A, Mughal N, **Moore LSP**. Experience of using Beta-D-glucan in assays in the intensive care unit. *Federation of Infection Societies, Birmingham*.
- 2017 Rudd R, **Moore LSP** et al. A rare case of cutaneous schistosomiasis; two years post-exposure. *26th European Academy of Dermatology & Venereology, Geneva*.
- 2017 Vutipongsatorn K, Rawson TM, Eades C, Holmes AH, Armstrong-James D, Loucaidou M, Abdolrasouli A, **Moore LSP**. Exploring the epidemiology and diversity of fungal infections in a tertiary renal unit in London, UK. *20th British Infection Association, London*.
- 2017 Eades C, Abdolrasouli A, **Moore LSP**. Antifungal susceptibility in vulvo-vaginal isolates: a six-year retrospective review of clinical specimens from a major London teaching laboratory. *20th British Infection Association, London*.
- 2017 Heard KL, Hughes S, Mughal N, Azadian BS, **Moore LSP**. Evaluating the impact of clinical decision support for antimicrobial stewardship: ICNET. *27th ECCMID, Vienna*.
- 2017 Abani O, Mughal N, Rawson TM, Azadian BS, **Moore LSP**. Demonstrating the effectiveness of sustainable, long term, bundled interventions to reduce blood culture contamination. *27th ECCMID, Vienna*.

- 2017 Rawson TM, Charani E, Chhabra S, **Moore LSP**, et al. Optimising intermittent vancomycin therapy using C-reactive protein: Investigating the role for AUC:EC50 in secondary care. *27th ECCMID, Vienna*.
- 2017 Rawson TM, Hernandez B, **Moore LSP**, et al. Patient-centred interventions to promote citizen engagement with infection-related decision making. *27th ECCMID, Vienna*.
- 2017 Rawson TM, Tivey A, Tsao A, Charani E, Gilchrist M, **Moore LSP**, et al. Evaluating behaviour change as part of Antimicrobial Stewardship interventions; a review of UK state-of-the-art conferences. *27th ECCMID, Vienna*.
- 2017 Rawson TM, **Moore LSP**, et al. A systematic review of clinical decision support systems for antimicrobial management: Are we failing to investigate these interventions appropriately? *27th ECCMID, Vienna*.
- 2017 Rawson TM, Charani E, **Moore LSP**, et al. Mapping decision pathways for acute infection management in UK secondary care: A qualitative study. *27th ECCMID, Vienna*.
- 2017 Kim B, Abdolrasouli A, Rawson TM, **Moore LSP**, et al. Exploring the epidemiology and diversity of fungal isolates in a large tertiary haematology unit. *27th ECCMID, Vienna*.
- 2016 Niruttan K, Rawson TM, **Moore LSP**. More than meets the eye: Investigating the microbiology of ophthalmic infections in a West London tertiary referral hospital. *Federation of Infection Societies, Edinburgh*.
- 2016 Philip A, Rawson TM, **Moore LSP**, et al. Closed loop controller systems for the precision delivery of vancomycin: An in silico proof-of-concept. *Federation of Infection Societies, Edinburgh*.
- 2016 Farrah H, **Moore LSP**, et al. A prospective multicentre observational study of mecillinam susceptibility to pathogenic urinary bacteria in a healthcare network in the UK. *Federation of Infection Societies, Edinburgh*.
- 2016 Tsao A, Tivey A, Rawson TM, **Moore LSP**, et al. Evaluating behaviour change as part of antimicrobial stewardship interventions: A review of UK state-of-the-art conferences. *Federation of Infection Societies, Edinburgh*.
- 2016 Nevin W, Tan L, Sriskandan S, **Moore LSP**. Disappearing dysgalactiae? Falling proportions of group C&G streptococcus in the community and in hospital in West London. *Federation of Infection Societies, Edinburgh*.
- 2016 Troughton R, Birgand G, **Moore LSP**, et al. Blogging in infectious diseases and clinical microbiology: assessment of the 'blogosphere' content. *Society for Healthcare Epidemiology of America Spring Conference, Atlanta*.
- 2016 Tivey A, Tsao A, Rawson TM, **Moore LSP**, et al. Investigating the impact of antimicrobial stewardship interventions at a cross-specialty level. *19th British Infection Association, London*.
- 2016 Baik JS, Philip A, Rawson TM, Charani E, Herrero-Vinas P, **Moore LSP**, et al. Investigating vancomycin therapy across secondary care pathways. *19th British Infection Association, London*.
- 2016 TP Butters, **LSP Moore**, et al. Striking Gold; a retrospective, multicentre observational study of *Delftia acidovorans* infections in West London. *19th British Infection Association, London*.
- 2016 McArdle AJ, Nijman R, Pledge A, **Moore LSP**, et al. Surveillance of paediatric sterile site isolates in a teaching hospital. *34th Annual Meeting of the European Society for Paediatric Infectious Diseases, Brighton*.
- 2016 Knight G, Costelloe C, **Moore LSP**, et al. Quantifying where selection occurs: mathematical modelling in antimicrobial resistance. *26th European Congress of Clinical Microbiology & Infectious Diseases, Amsterdam*.
- 2016 Butters T, Rawson TM, **Moore LSP**, et al. Assessment of cross-specialty engagement in antimicrobial stewardship; a cross-sectional, observational analysis of UK medical specialty curricula. *26th ECCMID, Amsterdam*.
- 2016 **Moore LSP**, et al. Refining national surveillance algorithms to facilitate local outbreak detection of carbapenem resistant organisms. *26th ECCMID, Amsterdam*.
- 2016 Farah H, **Moore LSP**, et al. Pivmecillinam; retrospective multicentre observational study of comparative urine susceptibilities. *26th ECCMID, Amsterdam*.
- 2016 Rawson TM, **Moore LSP**, et al. Addressing the final hurdle towards the elimination of Hansen's disease; a critical review of stigma in leprosy. *26th ECCMID, Amsterdam*.
- 2016 **Moore LSP**, et al. Real time antimicrobial resistance surveillance in critical care: identifying outbreaks of carbapenem resistant Gram negative bacteria from routinely collected data. *17th International Congress on Infectious Diseases, Hyderabad*.
- 2015 Birgand GJC, Castro-Sánchez E, **Moore LSP**, et al. Blogging in infectious diseases and clinical microbiology: Checking-up on the blogosphere. *Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, Paris*.
- 2015 Raisi-Estabragh Z, O'Connor L, **Moore LSP**, et al. Management and outcomes of enterococcal bacteraemia at a UK tertiary centre. *Federation of Infection Societies, Glasgow*.
- 2015 Rawson TM, **Moore LSP**, et al. Investigating coverage of antimicrobial stewardship across medical specialties; a cross-sectional study of leading UK & international conferences. *Federation of Infection Societies, Glasgow*.
- 2015 Rawson TM, **Moore LSP**, et al. Patient and public engagement in antimicrobial stewardship: a stakeholder analysis of shared decision making during infection management. *Federation of Infection Societies, Glasgow*.
- 2015 Charani E, Gharbi M, **Moore LSP**, et al. The effect of adding a mHealth intervention to a multimodal antimicrobial stewardship programme. *Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego*.
- 2015 Rawson TM, Gill D, Egan A, **Moore LSP**. An assessment of the perceived learning needs around antimicrobial prescribing among trainee doctors in West London. *Developing Health Educators for the Future, London*.
- 2015 Mughal N, **Moore LSP**, et al. Differential susceptibility to silver among clinical bacterial isolates: implications for clinical utility. *25th ECCMID, Copenhagen*.
- 2015 **Moore LSP**, et al. Delivering antimicrobial stewardship through a bespoke mobile-health application: REAIM analysis of three year impact. *25th ECCMID, Copenhagen*.

- 2015 Gharbi M, **Moore LSP**, et al. A cross-sectional study for optimizing prescribing practice among junior doctors in acute care in England. *25th ECCMID, Copenhagen*.
- 2015 Charani E, Gharbi M, **Moore LSP**, et al. The effect of a smartphone application on antimicrobial prescribing trends. *25th ECCMID, Copenhagen*.
- 2015 Pitty L, **Moore LSP**, et al. Discriminating carbapenemase production among carbapenem-resistant organisms in the clinical laboratory: analysis of the MALDI-TOF ertapenem hydrolysis assay. *25th ECCMID, Copenhagen*.
- 2015 McLeod M, Micallef C, Gharbi M, Gilchrist M, Charani E, **Moore LSP**, et al. mHealth: investigating the need for an evidence-based antimicrobial stewardship application for patients. *25th ECCMID, Copenhagen*.
- 2015 De Saram S, **Moore LSP**, et al. Losing your nerve: The challenges of managing Malignant Otitis Externa. *National OPAT Conference, London*.
- 2014 Gharbi M, **Moore LSP**, et al. A needs assessment study for optimising prescribing in secondary care junior doctors: The Antibiotic Prescribing Education among Doctors (APED) Study. *9th Hospital Infection Society Conference, Lyon*.
- 2013 **Moore LSP**, et al. Infectious Diseases & Medical Microbiology dual training: vertical and horizontal assessment of current training opportunities. *Federation of Infection Societies, Birmingham*.
- 2013 Freeman R, Charlett A, **Moore LSP**, et al. Statistical methods for the prospective detection of outbreaks within the hospital setting: differences in algorithm performance using national and local data. *23rd ECCMID, Berlin*.
- 2013 **Moore LSP**, et al. Indicators for bacteraemia in a UK tertiary ICU. *British Society for Antimicrobial Chemotherapy Spring Conference, London*.
- 2012 **Moore LSP**, et al. Treatment of skull base infections & malignant otitis externa using OPAT. *Federation of Infection Societies, Liverpool*.
- 2012 Freeman R, **Moore LSP**, et al. The utility of electronic surveillance for monitoring healthcare associated infections: a systematic review. *Health Protection Conference, Warwick*.
- 2012 **Moore LSP**, et al. Antimicrobial resistance at the United Kingdom's first Academic Health Sciences Centre. *22nd ECCMID, London*.
- 2012 Leslie A, **Moore LSP**, et al. A case of toxigenic cutaneous *Corynebacterium ulcerans*. *Health Protection Forum, London*.
- 2011 Charani E, Lawson W, Mookerjee S, Wickens H, Jacklin A, **Moore LSP**, et al. Developing a smartphone app to support antimicrobial stewardship and clinical decision making. *Federation of Infection Societies, Manchester*.
- 2011 Logan J, Sullivan C, **Moore LSP**. Reducing adult blood culture contaminants. *International Forum on Quality and Safety In Healthcare, Amsterdam*.
- 2010 Shepherd F, **Moore LSP**, et al. Oseltamivir associated supraventricular tachyarrhythmia. *Society of Acute Medicine 4th International Conference, Edinburgh*.

TEACHING & LEARNING

Research supervision

Imperial College London:

2022-date PhD supervision: Daniel Short, Akish Luintel.

2020-date PhD review panel: James Mcleod, Paul Arkell, Vasin Vasikasin.

Lectures & seminars:

Imperial College London:

2010-date MBBS (*40hrs per annum*)

2016-date MSc Genes Drugs and Stem Cells (*2hrs per annum*)

2016-2020 BSc Surgery and Cancer (*2hrs per annum*)

2012-2020 BSc Gastroenterology & Hepatology (*2hrs per annum*)

2014-2018 MSc Public Health (*4 hours per annum*)

2013-2014 MSc Infection (*2hrs per annum*)

2012-2014 MSc Infection Management for Pharmacists (*2hrs per annum*)

2016-2019 Imperial Introduction to Intensive care (I3): Postgraduate medical education (*6 hours per annum*)

2012-2014 Bucks New University: PGCert Principles & Practice of Infection Prevention & Control (*2hrs per annum*)

2012-2014 London Deanery: Acute Care Common Stem/Acute Medicine (*4hrs per annum*)

2015-2016 Creating Healthy Active Local Kids (CHALK): Primary care childhood obesity (*8 hours per annum*)

2014-2016 PasTest: Postgraduate medical education (*14hrs per annum*)

2014-2017 Hammersmith Medicine: Postgraduate medical education (*21hrs per annum*)

Clinical teaching:

2003-date Foundation year, Core medical, Specialty trainees, Allied Healthcare professionals (*40 hours per annum*)

2003-date Grand round presentations (*annually*)

2010-2013 Clinical infectious diseases departmental seminars (*20hrs per annum*)

2008-13 Nurse sepsis seminars (*annually*)

Examiner:

2019-date Royal College of Pathologists

2016-date Imperial College London

2013-2014 London Office of the Lee Kong Chian School of Medicine

2005-2009 Queen Mary University of London

Public communication:

2019-date Media Spokesperson, Healthcare Infection Society

2013-date Social media research dissemination: *Twitter: @dr_luke_moore, Youtube, Imperial College Website*

2015 NIHR Invention for Innovation Patient & Public event

2015 MRC Research, Innovate, Grow event

2013-2015 Imperial College Science Festival and 'Big Science' media event

CLINICAL QUALITY IMPROVEMENT

- 2022 COVID-19 antigen lateral flow assay implementation. *Chelsea & Westminster NHS Foundation Trust, London.*
2021 COVID-19 dnaNudge PCR implementation. *Chelsea & Westminster NHS Foundation Trust, London.*
2021 Procalcitonin utilisation and impact analysis. *Chelsea & Westminster NHS Foundation Trust, London.*
2020 COVID-19 Testing pathways/assay development. *Chelsea & Westminster NHS Foundation Trust, London.*
2020 COVID-19 Treatment pathways. *Chelsea & Westminster NHS Foundation Trust, London.*
2019 Group B Streptococcal disease in maternity. *Chelsea & Westminster NHS Foundation Trust, London.*
2019 Serosep PCR panel for enteric infections. *Chelsea & Westminster NHS Foundation Trust, London.*
2019 Helminth serology testing pathways. *Chelsea & Westminster NHS Foundation Trust, London.*
2018 Management of suspected MERS inpatients. *Chelsea & Westminster NHS Foundation Trust, London.*
2018 Rare and Imported Pathogens Laboratory Testing. *North West London Pathology, London.*
2018 Indwelling urinary catheter use. *Chelsea & Westminster NHS Foundation Trust, London.*
2018 16S rRNA referral pathways. *North West London Pathology, London.*
2018 Panton Valentine Leukocidin testing practice. *North West London Pathology, London.*
2017 Critical care antifungal stewardship. *Chelsea & Westminster NHS Foundation Trust, London.*
2017 Pseudomonas aeruginosa bacteraemia management. *North West London Pathology, London.*
2017 Staphylococcus aureus bacteraemia management. *Chelsea & Westminster NHS Foundation Trust, London.*
2017 Pyelonephritis ambulatory care referral pathways. *Chelsea & Westminster NHS Foundation Trust, London.*
2016 Blood culture contaminants; long term impact of a bundle. *North West London Pathology, London.*
2011-15 Antimicrobial policy; point of care mHealth application. *Imperial College Healthcare NHS Trust, London.*
2014 Viral haemorrhagic fever; clinical guideline development. *Imperial College Healthcare NHS Trust, London.*
2012 Cellulitis - optimising outpatient antimicrobial pathways. *Imperial College Healthcare NHS Trust, London.*
2011 Renal antimicrobial resistance; addressing prescribing. *Imperial College Healthcare NHS Trust, London.*
2010 Urosepsis; optimising diagnostic pathways in the acute setting. *West Middlesex University Hospital, London.*
2009 Ertapenem; new drug formulary submission. *West Middlesex University Hospital, London.*
2009 Urinary tract infections; the role of pivmecillinam. *Chelsea & Westminster Foundation Hospital, London.*
2008 Paediatric bacteraemias; reducing contaminants. *Chelsea & Westminster Foundation Hospital, London.*
2007 Haematology bacteraemias; indicators & utility. *University College Hospital, London.*
2006 Interspecialty inpatient referrals; optimising interactions. *Whipps Cross University Hospital, London.*
2005 Quinolone prescription in the elderly; reducing use. *Whipps Cross University Hospital, London.*

CONTINUING PROFESSIONAL DEVELOPMENT

- 2013/17/19/ 22 Good clinical practice. *National Institute for Health and Care Research.*
2010/12/14/ 15/16/17/18 /20/21/22 Federation of infection societies. *British Infection Association/British Society of Antimicrobial Chemotherapy/Society for General Microbiology/Healthcare Infection Society.*
2012/13/16/ 17/18/19/21 /22 European congress on clinical microbiology & infectious diseases. *European Society of Clinical Microbiology & Infectious Diseases.*
2012/14/16 /18/20/22 Information governance. *Imperial College Healthcare NHS Trust/Chelsea & Westminster Foundation Hospital.*
2017 Influencing others and changing behaviour. *DIPC Development Programme.*
2017 Multi-disciplinary management of the critically ill burns patient. *Chelsea & Westminster NHS Foundation Trust.*
2017 Making the most of one off teaching. *Imperial College London.*
2017 Practical guide to laboratory teaching. *Imperial College London.*
2016 Introduction to communication with the media. *Science Media Centre.*
2016 Leadership and management. *University College London Health Partners.*
2004/08/11 /16 Advanced life support certified provider. *UK Resuscitation Council.*
2015 Yellow fever vaccination training. *National Travel Health Network and Centre.*
2015 Introduction to infectious diseases modelling. *Infectious Diseases Research Network, London.*
2015 Data management and statistical analysis using stata. *Imperial College London.*
2015 Introduction to Statistics using Stata. *Imperial College London.*
2015 Small group teaching in the faculty of medicine. *Imperial College London.*
2015 Problem based learning in the faculty of medicine. *Imperial College London.*
2014 Intellectual property and its importance to researchers. *Imperial College London.*
2014 Teaching and learning in the faculty of medicine. *Imperial College London.*
2014 Clinical implications of whole genome sequencing in infectious diseases. *University of Cambridge.*
2010 Food & water microbiology. *Health Protection Agency.*